Business Wire

Amylgen and Neuron-Experts Announce Strategic Partnership

Share

Amylgen and Neuron-Experts, two leading preclinical CROs specialized in CNS pathologies, today announced an exclusive and strategic partnership that combines their respective in-vivo and in-vitro expertise to provide a new offering for a rapid efficacy assessment of compounds in neurodegenerative diseases.

Under this agreement, Amylgen and Neuron-Experts, who both serve biotechnology, pharmaceutical and nutraceutical companies as part of their preclinical development for CNS pathologies, will jointly provide customers with a new, rapid and comprehensive offering to evaluate on in-vitro and in-vivo models the efficacy of compounds in neurodegenerative diseases. This new preclinical offering will provide a first efficacy proof of concept to select the most effective compound among several leads. Subsequent studies will be possible to further investigate the therapeutical benefit, the elucidation of action mecanism, the therapeutical strategy...

Helping our clients achieve their strategic preclinical objectives is our core focus and we continue to build out our suite of services and partnerships to support that mission,” said Vanessa Villard, CEO, Amylgen. “In Neuron-Experts, we chose a partner who not only provides best-in-class expertise in CNS in-vitro testing, but also shares our deep commitment to ensuring mutual clients have access to the most comprehensive and effective solutions to evaluate the clinical potential of their compounds.

As a trusted partner to biotech companies for their preclinical development in neurodegenerative diseases, we believe in the great value to offer a rapid efficacy assessment of new compounds combining in-vitro and in-vivo testing as a primary proof of concept. We are honored to be partnered with Amylgen, a respected and innovative in-vivo preclinical CRO, to launch this new offering and together we look forward to delivering significant value to our clients,” said Remy Steinschneider, CEO, Neuron-Experts.

Amylgen will market this joint offering, that will be launched as a first step to assess the efficacy of compounds on Alzheimer’s Disease. The offer will be rapidly extended to other neurodegenerative diseases.

About Neuron-Experts
Neuron Experts is a Contract Research Organization (CRO) specialized in the in-vitro study of neuro-active compounds. The company uses its own tests based on primary neuronal cell cultures modelling neurodegenerative diseases and neuronal impairment-induced skin disorders.

About Amylgen
Amylgen is a privately held preclinical CRO offering a unique combination of validated in-vivo rodent models and a full range testing allowing fast and predictive screening of the effects of drugs and nutraceuticals on brain health. Thanks to background in the Industry, we guarantee satisfaction and provide our services with nonconditional high quality standards and with full awareness of time sensitive deadlines in the frame of critical phases of your product development.

Contact information

Laura Ceolin - contact@amylgen.com
www.amylgen.fr
Tel: +33 4 67 63 99 87

Neuron-Experts
contact@neuronexperts.com
www.neuronexperts.com
Tel: +33 4 86 01 11 95

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Iguazio Raises $24M to Accelerate Growth and Global Penetration of its Data Science Platform27.1.2020 15:00:00 EETPress release

Iguazio, the data science platform for real time machine learning applications, today announced that it has raised $24M of funding. The round was led by INCapital Ventures, with participation from existing and new investors, including Pitango, Verizon Ventures, Magma Venture Partners, Samsung SDS, Kensington Capital Partners, Plaza Ventures and Silverton Capital Ventures. The funds will be used by Iguazio to accelerate its growth and expand the reach of its data science platform to new global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005301/en/ Iguazio co-founders Yaron Segev (left), Yaron Haviv, and Asaf Somekh. Photo: Yanai Yechiel The demand for AI applications is on the rise. According to Gartner, AI augmentation alone will create $2.9 trillion of business value in 2021. However, there are still many challenges in deploying AI solutions in an effective and scalable way. An estimated 87% of data scienc

Iguazio Deployed by Payoneer to Prevent Fraud with Real-time Machine Learning27.1.2020 15:00:00 EETPress release

Iguazio, the data science platform for real time machine learning applications, today announced that Payoneer, the digital payment platform empowering businesses around the world to grow globally, has selected Iguazio’s platform to provide its 4 million customers with a safer payment experience. By deploying Iguazio, Payoneer moved from a reactive fraud detection method to proactive prevention with real-time machine learning and predictive analytics. Payoneer overcomes the challenge of detecting fraud within complex networks with sophisticated algorithms tracking multiple parameters, including account creation times and name changes. However, prior to using Iguazio, fraud was detected retroactively, enabling customers to only block users after damage had already been done. Payoneer is now able to take the same sophisticated machine learning models built offline and serve them in real-time against fresh data. This ensures immediate prevention of fraud and money laundering with predictiv

Oasis Smart SIM Achieves Certification of HELIOS eUICC in Accordance With GSMA M2M Specifications27.1.2020 14:48:00 EETPress release

Oasis’ newly certified HELIOS eUICC Operating System can be used in any type of mobile device, whilst guaranteeing total security and interoperability with the rest of the eSIM ecosystem. This certification was done by an independent accredited laboratory following the GSMA SGP.16 v1.0 validation requirements and processes. Rigorous testing of HELIOS eUICC by a third-party lab verified the compliance with GSMA specifications and standard interoperability. The goal is to ensure that mobile network operators are able to use HELIOS eUICC in complete security and in a reliable manner. To address the market needs, HELIOS eUICC is available both as a software-only Operating System or preloaded into Secure Elements from leading semiconductor companies. Its complete interoperability ensures that HELIOS eUICC can be remotely managed by any Subscription Manager compliant with the GSMA specifications. Patrick Cao, Chief Operating Officer, said “We are proud to obtain this certification. This conf

A Better Alternative to Banking - ClubSwan.com27.1.2020 12:00:00 EETPress release

ClubSwan.com, the leader in membership driven financial solutions, further expands its innovative alternative banking capabilities to key global markets. As traditional financial institutions continually struggle to provide innovative and meaningful ways to bring value to individual and corporate customers and as digital assets/crypto currencies are experiencing global growth, ClubSwan.com continues to evolve to meet the efficiencies and demands that these new assets and our customers require and to which traditional banks have no answer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005046/en/ Instead, closed bank accounts, rejected transactions, crippling delays with customers receiving their funds (if at all) are all the norm with traditional banks. To add to this dilemma, the availability of trustworthy solutions where customers have peace of mind for both crypto assets and traditional currencies have been non-exi

GSMA Recognizes Turkcell and P.I. Works for the Value of AI Based Network Automation27.1.2020 10:00:00 EETPress release

Turkcell and P.I. Works have been recognized by GSMA Future Networks Programme for achieving exceptional efficiency gains in network operations and ensuring superior customer experience. P.I. Works and Turkcell have successfully shown that the AI based, service aware network automation delivered stronger improvements as compared to conventional automation solutions. The details of the deployed solutions and their benefits are provided in a joint white paper authored by GSMA, Turkcell and P.I. Works under GSMA’s Future Networks Programme. To read the white paper please visit: https://www.gsma.com/futurenetworks/wiki/case-study-ai-use-cases-in-service-assurance/ GSMA Future Networks Programme intends to help operators share best practices and discover new opportunities that will enable them to reduce operational and capital expenditures. Given the success of the project, GSMA invited Turkcell and P.I. Works to join the program and provide insights for the AI-based, Service Aware Automate

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint27.1.2020 10:00:00 EETPress release

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (ADC), in patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy. The trial met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in objective response rate (ORR), as assessed by an independent review committee, in patients treated with DS-8201 versus investigator’s choice of chemotherapy (irinotecan or paclitaxel monotherapy). DS-8201 also showed a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint. The safety profile observed for DS-8201 in DESTINY-Gastric01 was consistent with previous clinical trials. These results c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom